Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 7Gynecologic 6Other hematologic neoplasm 5Genitourinary 5Breast 5Lymphoid 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1Head & Neck 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Stomatitis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Bacterial Infections 1Agammaglobulinemia 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Saline Solution × Other hematologic neoplasm × Clear all
NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05493800 2024-05-29

Capella

MitoImmune Therapeutics

Phase 2 Unknown
60 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Stomatitis, Hematologic Neoplasms

NCT04571645 2024-04-15

AML

Jazz Pharmaceuticals

Phase 3 Terminated
9 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02663622 2024-01-23

MK-7110-002

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
44 enrolled 27 charts
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

NCT01687387 2019-02-08

EFFIKIR

Innate Pharma

Phase 2 Completed
152 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡